NFE2L2 and diabetic kidney disease: In the current study, we screened digitoflavone as an effective Nrf2 activator in mouse mesangial cells and explored its therapeutic potential to slow the progression of diabetic nephropathy using a streptozotocin (STZ)-induced model of diabetes.